Cardiovascular Journal of Africa: Vol 28 No 6 (November/December 2017)

CARDIOVASCULAR JOURNAL OF AFRICA • Volume 28, No 6, November/December 2017

376

AFRICA

sion Cohort (PAPUCO) study: implementing a contemporary registry on

pulmonary hypertension in Africa.

Br Med J Open

2014;

(10): e005950.

13. Sliwa K, Lee GA, Carrington MJ, Obel P, Okreglicki A, Stewart S.

Redefining the ECG in urban South Africans: electrocardiographic find-

ings in heart disease-free Africans.

Int J Cardiol

2013;

167

(5): 2204–2209.

14. Lau EMT, Tamura Y, McGoon MD, Sitbon O. The 2015 ESC/ERS

Guidelines for the diagnosis and treatment of pulmonary hypertension: a

practical chronicle of progress.

Eur Respir J

2015;

(4): 879–882.

15. Stewart S, Wilkinson D, Becker A, Askew D, Ntyintyane L, McMurray JJ,

et al

. Mapping the emergence of heart disease in a black, urban population

in Africa: the Heart of Soweto Study.

Int J Cardiol

2006;

108

(1): 101–108.

16. Altman DG, Bland JM. Diagnostic tests 2: Predictive values.

Br Med J

1994;

309

(6947): 102.

17. Altman DG, Bland JM. Diagnostic tests. 1: Sensitivity and specificity.

Med J

1994;

308

(6943): 1552.

18. Karaye KM, Sani MU. Electrocardiographic abnormalities in patients

with heart failure.

Cardiovasc J Afr

2008;

(1): 22–25.

19. Dzudie A, Milo O, Edwards C, Cotter G, Davison BA, Damasceno A,

et al.

Prognostic significance of ECG abnormalities for mortality risk in

acute heart failure: insight from the Sub-Saharan Africa Survey of Heart

Failure (THESUS-HF).

J Card Fail

2014;

(1): 45–52.

20. Al-Naamani K, Hijal T, Nguyen V, Andrew S, Nguyen T, Huynh T.

Predictive values of the electrocardiogram in diagnosing pulmonary hyper-

tension.

Int J Cardiol

2008;

127

(2): 214–218.

21. Henkens IR, Mouchaers KT, Vonk-Noordegraaf A, Boonstra A, Swenne

CA, Maan AC,

et al.

Improved ECG detection of presence and severity of

right ventricular pressure load validated with cardiac magnetic resonance

imaging.

Am J Physiol Heart Circ Physiol

2008;

294

(5): H2150–157.

22. Nagai T, Kohsaka S, Murata M, Okuda S, Anzai T, Fukuda K,

et al

Significance of electrocardiographic right ventricular hypertrophy in

patients with pulmonary hypertension with or without right ventricular

systolic dysfunction.

Intern Med

2012;

(17): 2277–2283.

23. Ahearn GS, Tapson VF, Rebeiz A, Greenfield JC, Jr. Electrocardiography

to define clinical status in primary pulmonary hypertension and pulmo-

nary arterial hypertension secondary to collagen vascular disease.

Chest

2002;

122

(2): 524–527.

24. Hoeper MM, Lee SH, Voswinckel R, Palazzini M, Jais X, Marinelli A,

. Complications of right heart catheterization procedures in patients with

pulmonary hypertension in experienced centers.

J Am Coll Cardiol

2006;

(12): 2546–2552.

25. Janda S, Shahidi N, Gin K, Swiston J. Diagnostic accuracy of echocar-

diography for pulmonary hypertension: a systematic review and meta-

analysis.

Heart

2011;

(8): 612–622.

26. Sun PY, Jiang X, Gomberg-Maitland M, Zhao QH, He J, Yuan P,

. Prolonged QRS duration: a new predictor of adverse outcome in

idiopathic pulmonary arterial hypertension.

Chest

2012;

141

(2): 374–380.

27. Rich JD, Thenappan T, Freed B, Patel AR, Thisted RA, Childers R,

et al

QTc prolongation is associated with impaired right ventricular function

and predicts mortality in pulmonary hypertension.

Int J Cardiol

2013;

167

(3): 669–676.

Confidence Through Clinical and Real World Experience

1-3

Millions of Patients Treated Worldwide Across Multiple Indications

#1 Scripted Non-VKA Oral Anticoagulant by Cardiologists*

*Impact RX Data 2016

NOAC: Non Vitamin K Oral Anticoagulant

REFERENCES:

1. Patel M.R., Mahaffey K.W., Garg J.

et al

. Rivaroxaban versus warfarin in non-valvular atrial fi brillation.

N Engl J Med

. 2011;365(10):883–91. 2. Tamayo S., Peacock W.F., Patel M.R.,

et al

. Characterizing

major bleeding in patients with nonvalvular atrial fi brillation: A pharmacovigilance study of 27 467 patients taking rivaroxaban.

Clin Cardiol

. 2015;38(2):63–8. 3. Camm A.J., Amarenco P., Haas S.

et al

. XANTUS: A

Real-World, Prospective, Observational Study. 4. Calculation based on IMS Health MIDAS, Database: Monthly Sales January 2017.

S4 Xarelto 15: Each film-coated tablet contains rivaroxaban 15 mg. Reg. No: 46/8.2/0111; Namibia NS2 : 12/8.2/0006; S2 Botswana: BOT1302296; Zimbabwe: PP10 Reg. 2017/10.2/5363

S4 Xarelto 20: Each film-coated tablet contains rivaroxaban 20 mg. Reg. No: 46/8.2/0112;Namibia NS2 : 12/8.2/0007; S2 Botswana: BOT1302297; Zimbabwe: PP10 Reg. 2017/10.2/5364

PHARMACOLOGICAL CLASSIFICATION:

A.8.2 Anticoagulants.

INDICATIONS:

(1) Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (SPAF); (2) Treatment of deep vein thrombosis

(DVT) and for the prevention of recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE); (3) Treatment of pulmonary embolism (PE) and for the prevention of recurrent pulmonary embolism (PE) and deep

vein thrombosis (DVT). For full prescribing information, refer to the package insert approved by the Medicines Regulatory Authority (MCC).

HCR:

Bayer (Pty) Ltd, Co. Reg. No.: 1968/011192/07, 27 Wrench Road, Isando,

1609. Tel: 011 921 5044 Fax: 011 921 5041.

L.ZA.MKT.GM

06.2017.1808